Publication & Date: Journal of Affective Disorders 240:130-136 (2018) Investigators: A Tendler, R Gersner, Y Roth, A ZangenRead More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
An acute course of dTMS typically involves treatments delivered 5 days a week, for 4 weeks.Should more treatments be given if the patient has not responded? Data are needed to inform decisions about the best next steps for acute non-responders.
To characterize response among acute-phase non-responders in a randomized controlled trialof deep repetitive transcranial magnetic stimulation (dTMS) monotherapy for medication-resistantdepression.
Summary statistics and Kaplan-Meier curves were used to characterize outcomes of 33medication-free BrainswayTMdTMS non-responders to double blind but active treatment at the end of 4 weeks (20 sessions), who then continued double blind but active twice weekly treatment for up to 12 additional weeks.
24 participants (72.7%) achieved responder status during at least one rating with dTMScontinuation -20 (60.6%) within four weeks, with 13 (39.4%) consistently meeting response criteria for the duration of the study. 20 (63.6%) achieved remission status at some point during treatment continuation.
A significant proportion of acute course non-responders to dTMS treatment eventuallyrespond with continued treatment. Continuing TMS treatment beyond the acute course for non-responders may result in eventual response in over half of these individuals.